FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2016054341> ?p ?o ?g. }

• W2016054341 endingPage "446" @default.
• W2016054341 startingPage "439" @default.
• W2016054341 abstract "ORL-1 agonists have been proposed as potential therapeutics for substance abuse based on their propensity to counter the effects of mu opioid agonists in several systems, and to inhibit mesolimbic dopamine release, while mostly being devoid of aversive properties. In support of this, ORL-1 agonists have been shown to block the acquisition of morphine conditioned place preference (CPP). We investigated the effect of Ro 64-6198, a systemically active ORL-1 agonist, on the acquisition, expression, extinction, and reinstatement of morphine (20 mg/kg, s.c.) CPP in C57BL6/J mice. Similar to effects obtained with nociceptin/orphanin FQ, Ro 64-6198 (1 mg/kg, i.p.) blocked the acquisition of morphine CPP when given 15 min prior to each drug and vehicle conditioning session. This effect was not due to state dependent learning, since when tested again in the presence of Ro 64-6198 or vehicle no CPP was observed. Administration of Ro 64-6198 (0.3 or 1 mg/kg, i.p.) on the test day alone, in a separate group of animals, failed to block the expression of morphine CPP. Another group of mice was conditioned to morphine to develop CPP, and then exposed to the CPP chambers in the absence of drug once a day for 30 min to extinguish the CPP. Ro 64-6198 (1 mg/kg, i.p.) given 15 min prior to each session during extinction did not affect the rate of extinction. Finally, another group was conditioned to morphine, their CPP extinguished and subsequently reinstated by a priming injection of morphine (20 mg/kg, s.c.). Ro 64-6198 (1 mg/kg, i.p.), given 15 min prior to the priming injection, blocked reinstatement of morphine CPP. These results suggest that Ro 64-6198's effects may be limited to attenuation of the acute rewarding effects of morphine." @default.
• W2016054341 created "2016-06-24" @default.
• W2016054341 creator A5004941560 @default.
• W2016054341 creator A5009230887 @default.
• W2016054341 creator A5009821453 @default.
• W2016054341 date "2005-09-01" @default.
• W2016054341 modified "2023-10-17" @default.
• W2016054341 title "The effect of a systemically active ORL-1 agonist, Ro 64-6198, on the acquisition, expression, extinction, and reinstatement of morphine conditioned place preference" @default.
• W2016054341 cites W1598044684 @default.
• W2016054341 cites W1968375954 @default.
• W2016054341 cites W1971493573 @default.
• W2016054341 cites W1976799208 @default.
• W2016054341 cites W1980545520 @default.
• W2016054341 cites W1981048284 @default.
• W2016054341 cites W1988185716 @default.
• W2016054341 cites W1991377640 @default.
• W2016054341 cites W1994867599 @default.
• W2016054341 cites W1996561349 @default.
• W2016054341 cites W2013380848 @default.
• W2016054341 cites W2016562510 @default.
• W2016054341 cites W2020262342 @default.
• W2016054341 cites W2022150892 @default.
• W2016054341 cites W2022334415 @default.
• W2016054341 cites W2022560389 @default.
• W2016054341 cites W2022774723 @default.
• W2016054341 cites W2022948613 @default.
• W2016054341 cites W2026594079 @default.
• W2016054341 cites W2026689443 @default.
• W2016054341 cites W2032934611 @default.
• W2016054341 cites W2034128256 @default.
• W2016054341 cites W2035805507 @default.
• W2016054341 cites W2036685400 @default.
• W2016054341 cites W2037662305 @default.
• W2016054341 cites W2038992250 @default.
• W2016054341 cites W2040421480 @default.
• W2016054341 cites W2048265158 @default.
• W2016054341 cites W2051455839 @default.
• W2016054341 cites W2053863531 @default.
• W2016054341 cites W2055246318 @default.
• W2016054341 cites W2056529600 @default.
• W2016054341 cites W2058611932 @default.
• W2016054341 cites W2064420586 @default.
• W2016054341 cites W2066624199 @default.
• W2016054341 cites W2067645781 @default.
• W2016054341 cites W2068648717 @default.
• W2016054341 cites W2072158907 @default.
• W2016054341 cites W2077530921 @default.
• W2016054341 cites W2081395043 @default.
• W2016054341 cites W2082307932 @default.
• W2016054341 cites W2123094625 @default.
• W2016054341 cites W2124707889 @default.
• W2016054341 cites W2135903564 @default.
• W2016054341 cites W2139060090 @default.
• W2016054341 cites W2166290059 @default.
• W2016054341 cites W2180074457 @default.
• W2016054341 cites W2232667923 @default.
• W2016054341 cites W2268125251 @default.
• W2016054341 cites W2407372133 @default.
• W2016054341 doi "https://doi.org/10.1016/j.neuropharm.2005.04.008" @default.
• W2016054341 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/15919100" @default.
• W2016054341 hasPublicationYear "2005" @default.
• W2016054341 type Work @default.
• W2016054341 sameAs 2016054341 @default.
• W2016054341 citedByCount "76" @default.
• W2016054341 countsByYear W20160543412012 @default.
• W2016054341 countsByYear W20160543412013 @default.
• W2016054341 countsByYear W20160543412014 @default.
• W2016054341 countsByYear W20160543412015 @default.
• W2016054341 countsByYear W20160543412016 @default.
• W2016054341 countsByYear W20160543412017 @default.
• W2016054341 countsByYear W20160543412018 @default.
• W2016054341 countsByYear W20160543412019 @default.
• W2016054341 countsByYear W20160543412020 @default.
• W2016054341 countsByYear W20160543412021 @default.
• W2016054341 countsByYear W20160543412022 @default.
• W2016054341 countsByYear W20160543412023 @default.
• W2016054341 crossrefType "journal-article" @default.
• W2016054341 hasAuthorship W2016054341A5004941560 @default.
• W2016054341 hasAuthorship W2016054341A5009230887 @default.
• W2016054341 hasAuthorship W2016054341A5009821453 @default.
• W2016054341 hasConcept C101991246 @default.
• W2016054341 hasConcept C105795698 @default.
• W2016054341 hasConcept C125439840 @default.
• W2016054341 hasConcept C170493617 @default.
• W2016054341 hasConcept C185592680 @default.
• W2016054341 hasConcept C199289684 @default.
• W2016054341 hasConcept C2777389121 @default.
• W2016054341 hasConcept C2778938600 @default.
• W2016054341 hasConcept C2781063702 @default.
• W2016054341 hasConcept C33923547 @default.
• W2016054341 hasConcept C35124327 @default.
• W2016054341 hasConcept C45262634 @default.
• W2016054341 hasConcept C55493867 @default.
• W2016054341 hasConcept C71924100 @default.
• W2016054341 hasConcept C88016717 @default.
• W2016054341 hasConcept C98274493 @default.
• W2016054341 hasConceptScore W2016054341C101991246 @default.
• W2016054341 hasConceptScore W2016054341C105795698 @default.

• next